Compare LGIH & QDEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | QDEL |
|---|---|---|
| Founded | 2003 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2013 | 2022 |
| Metric | LGIH | QDEL |
|---|---|---|
| Price | $48.22 | $12.99 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 4 |
| Target Price | ★ $75.90 | $28.25 |
| AVG Volume (30 Days) | 360.1K | ★ 2.1M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.35 |
| EPS | ★ 0.09 | N/A |
| Revenue | $1,705,504,000.00 | ★ $2,730,200,000.00 |
| Revenue This Year | $2.32 | $3.51 |
| Revenue Next Year | $17.94 | $3.86 |
| P/E Ratio | $540.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.55 | $9.92 |
| 52 Week High | $69.42 | $35.58 |
| Indicator | LGIH | QDEL |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 54.42 |
| Support Level | $45.69 | $10.86 |
| Resistance Level | $49.51 | $17.78 |
| Average True Range (ATR) | 2.37 | 0.88 |
| MACD | 0.38 | 0.40 |
| Stochastic Oscillator | 76.19 | 83.45 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.